BR9915604A - Peptìdios inibidores de tgfbeta1 - Google Patents

Peptìdios inibidores de tgfbeta1

Info

Publication number
BR9915604A
BR9915604A BR9915604-0A BR9915604A BR9915604A BR 9915604 A BR9915604 A BR 9915604A BR 9915604 A BR9915604 A BR 9915604A BR 9915604 A BR9915604 A BR 9915604A
Authority
BR
Brazil
Prior art keywords
tgfbeta1
inhibitory peptides
peptides
compositions
inhibitory
Prior art date
Application number
BR9915604-0A
Other languages
English (en)
Other versions
BR9915604B1 (pt
Inventor
Ignacio Jose Ezquerro Saenz
Juan Jose Lasarte Sagastibelza
Jesus Prieto Valtuena
Francisco Borras Cuesta
Original Assignee
Inst Cientifico Tecnol Navarra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Cientifico Tecnol Navarra filed Critical Inst Cientifico Tecnol Navarra
Publication of BR9915604A publication Critical patent/BR9915604A/pt
Publication of BR9915604B1 publication Critical patent/BR9915604B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>PEPTìDIOS INIBIDORES DE TGFBETA1''<D>. Peptídios sintéticos antagonistas obtidos de TGFß1 ou de seus receptores no organismo, que podem ser usados, como tais ou como as seq³ências genéticas que os codificam e os sistemas recombinantes que os expressem, na produção de composições úteis para o tratamento de doenças hepáticas e mais particularmente em casos de fibrose. Essas composições podem incluir opcionalmente mimótopos de referidos peptídios ativos.
BRPI9915604-0A 1998-11-24 1999-11-23 peptÍdios antagonistas de inibidores de tgf-beta1 e seu uso. BR9915604B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP9802465 1998-11-24
ES009802465A ES2146552B1 (es) 1998-11-24 1998-11-24 Peptidos inhibidores de tgf/31
PCT/ES1999/000375 WO2000031135A1 (es) 1998-11-24 1999-11-23 PEPTIDOS INHIBIDORES DE TGFβ1

Publications (2)

Publication Number Publication Date
BR9915604A true BR9915604A (pt) 2001-08-07
BR9915604B1 BR9915604B1 (pt) 2011-07-26

Family

ID=8305903

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9915604-0A BR9915604B1 (pt) 1998-11-24 1999-11-23 peptÍdios antagonistas de inibidores de tgf-beta1 e seu uso.

Country Status (16)

Country Link
US (2) US7057013B1 (pt)
EP (1) EP1132403B1 (pt)
JP (5) JP3836677B2 (pt)
CN (1) CN1203091C (pt)
AT (1) ATE322505T1 (pt)
AU (1) AU767498B2 (pt)
BR (1) BR9915604B1 (pt)
CA (1) CA2352537C (pt)
CY (1) CY1105616T1 (pt)
DE (1) DE69930763T2 (pt)
DK (1) DK1132403T3 (pt)
ES (2) ES2146552B1 (pt)
PT (1) PT1132403E (pt)
RU (1) RU2232771C2 (pt)
SI (1) SI1132403T1 (pt)
WO (1) WO2000031135A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723473B2 (en) 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
JP2002087938A (ja) * 2000-09-11 2002-03-27 Shiseido Co Ltd 養毛剤及びそのスクリーニング方法
EP1534737A4 (en) * 2002-04-29 2007-10-31 Univ Saint Louis PEPTIDE ANTAGONISTS OF TGF-BETA FAMILY ELEMENTS AND THERAPEUTIC USES OF THESE ANTAGONISTS
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
CA2627298A1 (en) * 2005-10-24 2007-05-03 Proyecto De Biomedicina Cima, S.L. Use of tgf-.beta.1 inhibitor peptides in the preparation of an immune response modulating agent
US7582609B2 (en) 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
KR100879239B1 (ko) * 2007-04-19 2009-01-16 (주)케어젠 Tgfp-cap 펩타이드 및 그의 용도
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
WO2009029656A1 (en) 2007-08-27 2009-03-05 Auxagen, Inc. METHODS FOR INHIBITING TGF-β
JP4630914B2 (ja) 2008-04-14 2011-02-09 株式会社日本ハイポックス 肝線維化抑制剤
MX2010013759A (es) 2008-06-13 2011-05-25 Proyecto Biomedicina Cima Sl Conjugados para la administracion de compuestos biologicamente activos.
CN102159219B (zh) 2008-09-16 2015-06-24 圣路易斯大学 提高转化生长因子-β信号发送的方法
CA2750559A1 (en) * 2009-02-05 2010-08-12 Digna Biotech, S.L. Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides
ES2347627B1 (es) 2009-03-06 2011-10-10 Isdin, S.A. Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
KR100983182B1 (ko) * 2009-08-14 2010-09-20 (주)엔솔테크 신규 펩타이드 및 그 용도
MX2012005340A (es) 2009-11-05 2012-12-05 Proyecto Biomedicina Cima Sl Sistemas de expresion regulada.
RU2565539C2 (ru) * 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
CN102898508B (zh) * 2011-08-12 2014-04-30 北京大学第一医院 封闭TGF-β受体或IL-10受体的多肽、其药物组合物及其用途
JP5963757B2 (ja) 2011-09-05 2016-08-03 株式会社ポーラファルマ Etfbの細胞異常増殖への適用方法及び異常増殖抑制剤
CU24181B1 (es) * 2012-11-09 2016-04-25 Ct De Inmunología Molecular POLIPÉPTIDOS DERIVADOS DEL TGFß
KR102168088B1 (ko) 2013-03-14 2020-10-20 더 브리검 앤드 우먼즈 하스피털, 인크. 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법
JP6403217B2 (ja) 2013-07-30 2018-10-10 京都府公立大学法人 角膜内皮ecm治療薬
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
EP3804760A1 (en) * 2013-10-31 2021-04-14 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3685848B1 (en) 2013-11-21 2021-09-15 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
JP6955443B2 (ja) * 2014-08-01 2021-10-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 肺動脈性肺高血圧症の処置に関する方法および組成物
IL299964A (en) 2014-09-03 2023-03-01 Massachusetts Inst Technology Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β1的scFv-Fc二聚體
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CA3010610A1 (en) 2016-01-08 2017-07-13 The Brigham And Women's Hospital, Inc. Production of differentiated enteroendocrine cells and insulin producing cells
KR101791526B1 (ko) 2016-02-18 2017-11-01 (주)케어젠 발모 촉진 활성을 나타내는 펩타이드 및 이의 용도
KR101841748B1 (ko) 2016-02-18 2018-05-08 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CA3048220A1 (en) 2016-12-30 2018-07-05 Frequency Therapeutics, Inc. 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
KR101954214B1 (ko) * 2017-05-23 2019-03-06 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
US11866427B2 (en) 2018-03-20 2024-01-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
EP3837352A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
CN109432431B (zh) 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
US20220162182A1 (en) 2018-12-31 2022-05-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
KR102265432B1 (ko) 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
CN110511285B (zh) * 2019-08-27 2023-01-24 南京安吉生物科技有限公司 一种重组融合多肽及其应用
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
CN116867797A (zh) * 2020-12-23 2023-10-10 韩国科学技术研究院 能够抑制TGF-β信号传导的新型肽及其应用
KR20240000395A (ko) * 2022-06-22 2024-01-02 주식회사 유씨아이테라퓨틱스 TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
JPH06500574A (ja) * 1991-05-10 1994-01-20 ザ ソーク インスティテュート フォア バイオロジカル スタディーズ アクチビン/TGF―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
FR2720069A1 (fr) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Dérivés de facteurs de croissance et d'hormones de la superfamille des TGFB, procédé pour leur obtention et leurs applications biologiques.
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy

Also Published As

Publication number Publication date
ES2146552A1 (es) 2000-08-01
EP1132403B1 (en) 2006-04-05
PT1132403E (pt) 2006-07-31
ES2262349T3 (es) 2006-11-16
CA2352537A1 (en) 2000-06-02
CN1203091C (zh) 2005-05-25
US20070014767A1 (en) 2007-01-18
JP2002530431A (ja) 2002-09-17
CN1328569A (zh) 2001-12-26
DE69930763T2 (de) 2006-11-30
WO2000031135A1 (es) 2000-06-02
JP4002287B2 (ja) 2007-10-31
JP4237807B2 (ja) 2009-03-11
US7528226B2 (en) 2009-05-05
JP2007186519A (ja) 2007-07-26
ATE322505T1 (de) 2006-04-15
AU1507700A (en) 2000-06-13
CY1105616T1 (el) 2010-07-28
JP4272255B2 (ja) 2009-06-03
DK1132403T3 (da) 2006-08-14
JP2006241166A (ja) 2006-09-14
CA2352537C (en) 2011-11-15
AU767498B2 (en) 2003-11-13
JP4068654B2 (ja) 2008-03-26
ES2146552B1 (es) 2001-04-16
DE69930763D1 (en) 2006-05-18
JP3836677B2 (ja) 2006-10-25
BR9915604B1 (pt) 2011-07-26
EP1132403A1 (en) 2001-09-12
SI1132403T1 (sl) 2006-08-31
JP2008056685A (ja) 2008-03-13
JP2009040796A (ja) 2009-02-26
RU2232771C2 (ru) 2004-07-20
US7057013B1 (en) 2006-06-06

Similar Documents

Publication Publication Date Title
BR9915604A (pt) Peptìdios inibidores de tgfbeta1
ATE353640T1 (de) Antagoniste zur behandlung von cd11/cd18 adhäsionsrezeptor-vermittelten krankheiten
LT2000123A (lt) Bifenilsulfonamidai kaip dvigubi angiotenzino ir endotelino receptorių antagonistai
DK1534286T3 (da) Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
SG145698A1 (en) Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds
DE69905170T2 (de) Thiazolopyrimidinderivate
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
MXPA03010158A (es) Sulfonamidas.
ATE363531T1 (de) Claudin polypeptide
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ECSP003707A (es) Diazepanes
AR032548A1 (es) Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
NO20002408D0 (no) 5-HT1F antagonister
BR9915537A (pt) Gene prv-1 e sua utilização
DK0925333T3 (da) Froststabilisering af vandige overtræksmidler med frostbeskyttelsesproteiner
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof
TR199701646A2 (xx) Vitronektin-reseptör antagonistleri,üretimleri ve kullanımları
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES)

B25A Requested transfer of rights approved

Owner name: PROYECTO DE BIOMEDICINA CIMA, S.L. (ES)

Free format text: TRANSFERIDO DE: FUNDACION PARA LA INVESTIGACION MEDICA APPLICADA

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/07/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.